Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-05 03:15:17 UTC |
---|
Update Date | 2014-12-24 20:25:42 UTC |
---|
Accession Number | T3D2565 |
---|
Identification |
---|
Common Name | Promazine |
---|
Class | Small Molecule |
---|
Description | Promazine is only found in individuals that have used or taken this drug. It is a phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Promazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Promazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with promazine. |
---|
Compound Type | - Amine
- Antiemetic
- Antipsychotic Agent
- Dopamine Antagonist
- Drug
- Ether
- Metabolite
- Organic Compound
- Phenothiazine
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | 10-(3-(Dimethylamino)propyl)phenothiazine | Combelen | Frenil | N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine | N-(3-Dimethylaminopropyl)phenothiazine | N-Dimethylamino-1-methylethyl thiodiphenylamine | Prazine | Promazin | Promazina | Promazinum | Sparine | Talofen |
|
---|
Chemical Formula | C17H20N2S |
---|
Average Molecular Mass | 284.419 g/mol |
---|
Monoisotopic Mass | 284.135 g/mol |
---|
CAS Registry Number | 58-40-2 |
---|
IUPAC Name | dimethyl[3-(10H-phenothiazin-10-yl)propyl]amine |
---|
Traditional Name | promazine |
---|
SMILES | CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12 |
---|
InChI Identifier | InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3 |
---|
InChI Key | InChIKey=ZGUGWUXLJSTTMA-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzothiazines |
---|
Sub Class | Phenothiazines |
---|
Direct Parent | Phenothiazines |
---|
Alternative Parents | |
---|
Substituents | - Phenothiazine
- Alkyldiarylamine
- Diarylthioether
- Aryl thioether
- Tertiary aliphatic/aromatic amine
- Para-thiazine
- Benzenoid
- Tertiary amine
- Tertiary aliphatic amine
- Thioether
- Azacycle
- Organic nitrogen compound
- Hydrocarbon derivative
- Organopnictogen compound
- Organonitrogen compound
- Amine
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | |
---|
Chemical Roles | |
---|
Physical Properties |
---|
State | Liquid |
---|
Appearance | Oily liquid (5). |
---|
Experimental Properties | Property | Value |
---|
Melting Point | < 25°C | Boiling Point | 203-210°C at 3.00E-01 mm Hg | Solubility | 14.2 mg/L (at 24°C) | LogP | 4.55 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
GC-MS | GC-MS Spectrum - EI-B (Non-derivatized) | splash10-0a4r-9230000000-62cbfd979fa705bc6b5e | 2017-09-12 | View Spectrum | GC-MS | GC-MS Spectrum - EI-B (Non-derivatized) | splash10-053i-9470000000-c8ea76fcc1b124b82db0 | 2017-09-12 | View Spectrum | GC-MS | GC-MS Spectrum - CI-B (Non-derivatized) | splash10-000i-2090000000-c38077fbc5880feb7eab | 2017-09-12 | View Spectrum | GC-MS | GC-MS Spectrum - EI-B (Non-derivatized) | splash10-0a4r-9230000000-62cbfd979fa705bc6b5e | 2018-05-18 | View Spectrum | GC-MS | GC-MS Spectrum - EI-B (Non-derivatized) | splash10-053i-9470000000-c8ea76fcc1b124b82db0 | 2018-05-18 | View Spectrum | GC-MS | GC-MS Spectrum - CI-B (Non-derivatized) | splash10-000i-2090000000-c38077fbc5880feb7eab | 2018-05-18 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-0bt9-9380000000-4268602a9238fb15661c | 2017-09-01 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-000i-1090000000-ae84d127d484047e5016 | 2016-08-01 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-000l-5090000000-5d46ceef0ced8c3b4fd3 | 2016-08-01 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0006-9220000000-fb2bc50e3fc843771469 | 2016-08-01 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-001i-0090000000-149bf8914d943f700602 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-00aj-0940000000-c0e629447aac15d08168 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0002-2900000000-5d376e3b361f6d4469ce | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-000i-1090000000-eb710b269048129dc354 | 2021-09-24 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-000i-9020000000-e2fb252f33540e1240df | 2021-09-24 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0a4i-9100000000-7887c8f93cf8f9148ae9 | 2021-09-24 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-001i-0090000000-34b5b095a83ae223858e | 2021-09-24 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-001i-0490000000-8b3f6932ff0b667dd708 | 2021-09-24 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0002-0910000000-8b82ae7472d26c1d3bdb | 2021-09-24 | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0a4i-9430000000-708a7cbef8d61ce76846 | 2014-09-20 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Inhalation; dermal or skin contact; ingestion (MSDS, A308).
Absorption may be erratic and peak plasma concentrations show large interindividual differences. |
---|
Mechanism of Toxicity | Promazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Promazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Promazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with promazine. |
---|
Metabolism | Hepatic, primarily to N-desmethylpromazine and promazine sulfoxide. Absorption may be erratic and peak plasma concentrations show large interindividual differences. The metabolism occurs through oxidative processes mediated largely by hepatic microsomal and other drug metabolizing enzymes. Antoher step is the conjugaion with glucuronic acid. Other reactions include hydroxylation, demetylation, and sulfoxide formation. Moreover, metabolic alterations in side chain may also occur (1, 2). |
---|
Toxicity Values | LD50: 140 mg/kg (Intraperitoneal, Mouse) |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | Used as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | It has predominantly anticholinergic side effects, though extrapyramidal side effects are not uncommon either. Other effects include endocrine effects (such as gynaecomastia and menstrual disturbance), sensitivity to sunlight and haemolytic anaemia (1, 8). |
---|
Symptoms | Side effects include: extrapyramidal symptoms, drowsiness, weight gain, dry mouth, constipation, endocrine effects (such as gynaecomastia and menstrual disturbance), sensitivity to sunlight and haemolytic anaemia. |
---|
Treatment | In severe cases, consider supportive therapy. Maintain clear airway and adequate hydration. Anti-Parkinson drugs, as well as benztropine mesylate, and barbiturates can be use to relieve extrapyramidal symptoms (3). |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB00420 |
---|
HMDB ID | HMDB14564 |
---|
PubChem Compound ID | 4926 |
---|
ChEMBL ID | CHEMBL564 |
---|
ChemSpider ID | 4757 |
---|
KEGG ID | C07379 |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 8459 |
---|
BioCyc ID | CPD-7403 |
---|
CTD ID | Not Available |
---|
Stitch ID | Promazine |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Promazine |
---|
References |
---|
Synthesis Reference | DrugSyn.org |
---|
MSDS | Link |
---|
General References | - Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M: DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. Epub 2007 Nov 29. [18048412 ]
- Kakiuchi T, Tsukada H, Fukumoto D, Nishiyama S: Effects of aging on serotonin transporter availability and its response to fluvoxamine in the living brain: PET study with [(11)C](+)McN5652 and [(11)C](-)McN5652 in conscious monkeys. Synapse. 2001 Jun 1;40(3):170-9. [11304754 ]
- Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Ohkubo T, Sugawara K, Otani K: Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Feb;26(2):383-6. [11817517 ]
- Cubala WJ, Jakuszkowiak-Wojten K, Burkiewicz A, Wronska A: Promazine in the treatment of delusional parasitosis. Psychiatr Danub. 2011 Jun;23(2):198-9. [21685861 ]
- Budavari, S (ed) (1996). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc.
- Rossoff IS (1974). Handbook of Veterinary Drugs. New York: Springer Publishing Company.
- American Society of Hospital Pharmacists. Data supplied on contract from American Hospital Formulary Service and other current ASHP sources.
- Wikipedia. Promazine. Last Updated 26 July 2009. [Link]
- Drugs.com [Link]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Gene | Gene Symbol | Gene ID | Interaction | Chromosome | Details |
---|
|
---|